AstraZeneca’s COVID-19 Taskforce Starts With Calquence Trial
BTK Inhibitor Has Shown Results In Advanced COVID-19 Lung Disease
AstraZeneca will launch a global clinical trial for its blood cancer drug Calquence because it showed early respiratory promise in later-stage COVID-19 patients, those in intensive care units and on ventilators.
